Regeneron's Q4 Double-Digit Top and Bottom-Line Growth Propelled By Higher Sales From Eylea And Dupixent

Comments
Loading...
  • Regeneron Pharmaceuticals Inc (NASDAQ: REGNreported fourth-quarter earnings of $9.53 per share, which beat the analyst consensus estimate of $8.39. Quarterly sales of $2.42 billion increased 30% year-on-year, which was in line with expectations. The current quarter earnings benefited from a recovery in demand for its flagship eye drug (Eylea) and a jump in sales of its eczema drug, Dupixent (collaboration with Sanofi).
  • Physician-administered macular degeneration drug Eylea sales were hurt during the pandemic’s peak last year as patients were reluctant to visit doctors’ offices. Eylea sales were up 10% to $2,202 million during the quarter.
  • Sales from Dupixent increased 56% to $1,172 million after the European Commission extended the marketing authorization for Dupixent in the EU to include children 6 to 11 years of age with severe atopic dermatitis who are candidates for systemic therapy, resulting in incremental sales from this label expansion.
  • The company recorded sales of $145.5 million from REGEN-COV, its antibody cocktail for COVID-19, for which the company received FDA Emergency Use Authorization from the FDA in November 2020. Last month, the company inked a second agreement with the U.S. government for 1.25M additional REGEN-COV doses, resulting in $2.625B payments. 
  • Other products include Libtayo: $97.3M (+30%); Praluent: $100.9M (+24%); Kevzara: $71.5M (+20%).

Select milestones of 2021

  • Additional data from REGEN-COV Phase 3 portion of COVID-19 study in non-hospitalized patients.
  • Dupixent: FDA decision on sBLA and MAA submission for asthma in pediatrics (6–11 years of age).
  • Libtayo: FDA decision on marketing application (target action date of February 28 and March 3) and European Commission decision on regulatory submission for first-line advanced or metastatic non-small cell lung cancer, monotherapy, and advanced or metastatic basal cell carcinoma.
  • Price Action: REGN shares gained 3.4% at $516 in premarket trading on the last check Friday.
Overview Rating:
Speculative
50%
Technicals Analysis
66
0100
Financials Analysis
40
0100
Overview
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!